GLP-1 Agonists: Weight Loss with Health Benefits GLP-1 (glucagon-like peptide-1) agonists, such as Ozempic, Wegovy, and Monjouro, were initially designed to treat type 2 diabetes
Another systemic analysis in Hypertension found similar results (a median of 2.6 pounds gained) when evaluating eight randomized trials that each lasted over six months
Who should raise niacin with their provider before starting compounded tirzepatide
Nevertheless, debates will likely continue about the costs of these medications and their manufacturing locations, which could lead to market fluctuations
The short answer is that any kind of excessive weight can lead to an increased risk for various health conditions that are known to decrease not just our life expectancy, but our healthspan as well (or, how long we stay healthy)
Patients experiencing swelling or signs of severe dehydration ought to contact their healthcare provider immediately